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Rheumatic fever (RF) is the most important cause of acquired
heart disease in children and young adults worldwide.1 The
prevalence of RF and rheumatic heart disease is high in areas
with poor socio-economic conditions, overcrowding and
limited access to medical care .2 The option of valve re p l a c e m e n t
is not available in most instances. As a result RF and rheumatic
heart disease cause serious disability, premature death and
significant health care expenditure in developing countries.
The reduction in prevalence of RF in developed countries
preceded the introduction of antibiotics and is probably related
to the improvement in these non-medical factors. The severity
and prognosis of rheumatic heart disease depend on the extent
of the carditis and the frequency of recurrent attacks.
Prevention of RF may be considered to be prevention of the
initial attack (primary prevention) or prevention of recurrent
attacks (secondary prevention). The subject of primary
prevention of RF and treatment of streptococcal sore throat has
been reviewed recently.3 Secondary prevention is particularly
important since even an asymptomatic or optimally treated
group A streptococcal (GAS) throat infection can still trigger RF
recurrence. The options for secondary prevention are the use of
a vaccine against GAS and antibiotic chemoprophylaxis.
Unfortunately, the availability of a vaccine is still several years
away and antibiotic chemoprophylaxis is the only option
available at the moment. There are data to suggest that
continuous regular antibiotic prophylaxis can prevent or
significantly reduce the development of valvular damage and
the prevalence of rheumatic heart disease, with disappearance
of pre-existing heart murmurs and reduction in mortality.4,5 The
importance of secondary prevention is well appreciated and
several programmes have been established in developing
countries.6
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Background. People with a history of rheumatic fever (RF) are
at high risk of recurrent attacks and of developing rheumatic
heart disease following a streptococcal throat infection.
Giving penicillin to these people can prevent recurrent
attacks  of RF and subsequent rheumatic heart disease.
However, there is no agreement on the most effective method
of giving penicillin. 
Objectives. To assess the effects of different penicillin regimens
and formulations for preventing streptococcal infection and
RF recurrence.
Search strategy. We searched the Controlled Trials Register
(Cochrane Library Issue 2, 2001), Medline (January 1966 - July
2000), Embase (January 1985 - July 2000), reference lists of
articles, and contacted experts in the field. 
Selection criteria. Randomised and quasi-randomised studies
comparing: (i) oral with intramuscular penicillin; and (ii) 2- or
3-weekly with 4-weekly intramuscular penicillin in patients
with previous RF.
Data collection and analysis. Two reviewers independently
assessed trial quality and extracted data.
Main results. Six studies were included (1 707 patients). Data
were not pooled because of clinical and methodological
heterogeneity of the trials. Four trials (1 098 patients)
compared intramuscular with oral penicillin and all showed
that intramuscular penicillin was more effective in reducing
RF recurrence and streptococcal throat infections than oral
penicillin.   One trial (360 patients) compared 2-weekly with
4-weekly intramuscular penicillin. Penicillin given every 2
weeks was better at reducing RF recurrence (relative risk (RR)
0.52, 95% confidence interval (CI): 0.33 - 0.83) and
streptococcal throat infections (RR 0.60, 95% CI: 0.42 - 0.85).
One trial (249 patients) showed that 3-weekly intramuscular
penicillin injections reduced streptococcal throat infections
(RR 0.67, 95% CI: 0.48 - 0.92) compared with 4-weekly
intramuscular penicillin.
Conclusions. Intramuscular penicillin seemed to be more
effective than oral penicillin in preventing RF recurrence and
streptococcal throat infections. Two-weekly or 3-weekly
injections appeared to be more effective than 4-weekly
injections. However, the evidence is based on poor-quality
trials and the use of outdated formulations of oral penicillin.
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Penicillin is the drug of choice for the secondary prevention
of RF.7 However, there is uncertainty and controversy
regarding the most effective regimen for secondary prevention
of RF. Some authorities consider intramuscular injections of
benzathine penicillin to be more effective than tablets taken
every day.7-9 However, due to the perceived higher risk of
anaphylaxis and the dangers associated with the re-use of
needles still practised in some poor communities and the
discomfort of intramuscular injections, there is resistance to the
use of intramuscular penicillin. The safety issues regarding the
use of penicillin injections have resulted in government orders
prohibiting penicillin injections in hospitals and clinics.10
The aim of this systematic review was to summarise the
evidence for the use of penicillin for the secondary prevention
of RF and to identify the most effective regimen. This
information will be of help to policy makers, health
practitioners and researchers in this area.
Methods
Objectives
To examine the effects of the different penicillin regimens and
formulations for preventing streptococcal infection and RF
recurrence.
Inclusion criteria
Randomised controlled trials of at least 6 months’ duration
were assessed for inclusion.  
Children and adults with a history of RF with or without
current evidence of rheumatic heart disease, with the initial
diagnosis of RF based on the Jones criteria,11 modified Jones
criteria,12 and revised Jones criteria,13 were eligible for the study.
Types of interventions were as follows: ( i) daily oral
penicillin versus intramuscular penicillin; and (ii) 2-weekly or
3-weekly versus 4-weekly intramuscular penicillin.
The primary outcomes were RF recurrence, mortality related
to RF and rheumatic heart disease, and development of chronic
rheumatic heart disease. The secondary outcomes were
streptococcal throat infections, compliance and adverse events.
Search strategy
Using the Cochrane Heart Group strategy, we searched the
Controlled Trials Register (Cochrane Library Issue 2, 2001),
Medline (January 1966 - July 2000), Embase (1985 - July 2000)
and reference lists of articles. We contacted experts in the field
for unpublished or ongoing studies. 
One hundred and fifty-nine citations were retrieved from the
databases and two reviewers independently assessed their
titles and abstracts for possible inclusion. Studies fulfilling
inclusion criteria were appraised independently by the two
reviewers, who abstracted study characteristics and outcome
measures onto a pre-designed form. The aspects used to assess
the quality of included studies were the method of
randomisation, adequacy of concealment of treatment
allocation and the rate of completion of follow-up.
Data analysis
For each study the outcomes were summarised into relative
risks (RRs) and 95% confidence intervals (CIs). The chi-squared
heterogeneity test as well as visual inspection of the graphs
were used to test for homogeneity between the studies and a
significance level of less than 0.10 was interpreted as evidence
for heterogeneity.
Results
One hundred and fifty-nine potentially relevant citations were
retrieved through the search strategy and 136 of these were
excluded on the basis of title and abstract (Fig. 1). Twenty-three
papers were retrieved for more detailed evaluation. Fourteen of
these were excluded for the following reasons: not trials (5),
editorial on primary prevention (1), retrospective study (1),
trials comparing penicillin with another antibiotic (2),
pharmacokinetic outcomes (1), use of historical controls (2),
and follow-up period less than 6 months (2).
Included studies
Six studies were included in this review. We grouped the
studies into those comparing oral with intramuscular penicillin
(4 randomised trials, 1 098 patients), 2-weekly with 4-weekly
penicillin injections (1 randomised trial, 360 patients) and 3-
weekly with 4-weekly intramuscular penicillin injections (1
randomised trial, 249 patients). The trial durations ranged from
1 to 12 years. There was no statistical heterogeneity between
the studies. However, the results were not pooled because of
differences in trial methodologies and patient characteristics
across studies.
Participants
The ages of the participants ranged from 3 to 24 years.
Manifestations of RF in the previous attack were not uniform,
some having presented with carditis but with no residual
rheumatic heart disease, some having presented with arthritis,
and a few with chorea. Patients were followed up every month
or every 2 months at which time they were assessed for
clinical, bacteriological and serological markers of RF
recurrence and streptococcal throat infection.
Outcome measures
The diagnosis of RF was based on the modified Jones criteria in
the four earlier studies14-17 and the revised Jones criteria for the
latest studies.18,19 Streptococcal throat infections were reported
as clinical infection, positive throat culture or raised serological
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markers. The serological test done initially was antistreptolysin
O titre (ASOT). In cases where throat culture and ASOT were
positive, serial ASOT, hyaluronidase and antistreptokinase
were taken. One or all of the following means were used to
assess compliance: interview, tablet counts, or average number
of injections missed. However, although 6 of the studies
assessed compliance, only 2 reported this outcome. 15,18 
Intramuscular versus oral penicillin (Figs 2 and 3)
One thousand and ninety-eight  patients were included in the 4
studies, 561 receiving intramuscular penicillin and 537
receiving oral penicillin. There were 7 RF recurrences among
patients receiving intramuscular penicillin and 89 among
patients receiving oral penicillin. All 4 studies showed a
reduction in the risk of RF recurrence in patients receiving
intramuscular penicillin compared with those receiving oral
penicillin  (Feinstein et al.14 1959: RR 0.06, 95% CI: 0.01 - 0.48;
Wood et al.15 1964: RR 0.07, 95% CI: 0.02 - 0.27; Feinstein16 1965;
RR 0.04, 95% CI: 0.01 - 0.30; Feinstein et al.17 1968: RR 0.13, 95%
CI 0.04 - 0.41). There were 78 streptococcal throat infections
among patients receiving intramuscular penicillin and 313
among those receiving oral penicillin.  Three studies showed
significant reduction in streptococcal infection in the
intramuscular regimen compared with the oral regimen (Wood
et al.15 1964: RR 0.23, 95% CI: 0.16 - 0.34; Feinstein16 1965: RR
0.09, 95% CI: 0.05 - 0.17; Feinstein et al.17 1968: RR 0.29, 95% 
CI: 0.21 - 0.40). 
Two-weekly versus 4-weekly intramuscular
penicillin (Figs 4 and 5)
Three hundred and sixty patients were included in 1 study, 190
receiving 2-weekly injections and 170 receiving 4-weekly
Potentially relevant publications identified
and screened for retrieval:
156
151 (English), 5 (other languages)
Papers excluded on the basis of title and
abstract (generally due to lack of suitability
of study design or intervention)
136
Excluded reasons:
Retrospective study 1
Editorial on primary prevention 1
Not a trial 5
Comparison of penicillin v. other antibiotic2
Pharmacokinetic outcomes 1
Use of historical outcomes 2
Follow-up period less than 6 months 2
Total 14
Papers retrieved for more detailed
evaluation:
20
Papers included:     6
Categories of studies by interventions
under comparison: 6 overall
Intramuscular v. oral penicillin 4
2-weekly v. 4-weekly injections 1
3-weekly v. 4-weekly injections 1
Total 6
Fig. 1. The quorum statement.
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injections.19 There were 24 RF recurrences among patients
receiving 2-weekly injections and 41 among those receiving 
4-weekly injections (RR 0.52, 95% CI: 0.33 - 0.83). There were 38
streptococcal infections in the 2-weekly treated group and 57 in
the 4-weekly treated group (RR 0.60, 95% CI: 0.42 - 0.85). 
Three-weekly versus 4-weekly intramuscular
penicillin (Figs 6 and 7)
This comparison was made in 1 study with 249 patients, 124
receiving 3-weekly injections and 125 receiving 4-weekly
injections.18 There were 9 RF recurrences in the 3-weekly treated
group and 16 in the 4-weekly treated group but this difference
did not reach statistical significance (RR 0.57, 95% CI: 0.26 -
1.23). There were 39 streptococcal throat infections among
children receiving 3-weekly injections and 59 among those
receiving 4-weekly injections (RR 0.67, 95% CI: 0.48 - 0.92). This
study also reported patient compliance with 3-weekly and 
4-weekly injection programmes to be comparable.
Other outcomes
None of the studies reported on mortality. Adverse events were
not presented uniformly in the studies. Wood et al.15 provide 8-
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Review: Penicillin for secondary prevention of rheumatic fever
Comparison: 01 Intramuscular versus oral penicillin
Outcome: 01 Rheumatic fever recurrences
Study Intramuscular Oral RR (fixed) Weight RR (fixed)
or subcategory (n / N) (n / N) 95% CI (%) 95% CI
Feinstein et al.14 1 / 116 15 / 113 16.72 0.06 (0.01, 0.48)
Wood et al.15 2 / 146 30 / 143 33.35 0.07 (0.02, 0.27)
Feinstein16 1 / 136 18 / 101 22.73 0.04 (0.01, 0.30)
Feinstein et al.17 3 / 163 26 / 180 27.19 0.13 (0.04, 0.41)
0.01 0.1 1 10 100
Favours intramuscular Favours oral
Fig. 2. Relative risk (95%) of rheumatic fever recurrence for individuals treated with intramuscular or oral penicillin (CI = confidence interval; 
N = total number in group; n = number with outcome).
Review: Penicillin for secondary prevention of rheumatic fever
Comparison: 01 Intramuscular versus oral penicillin
Outcome: 02 Streptococcal throat infections
Study Intramuscular Oral RR (fixed) Weight RR (fixed)
or subcategory (n / N) (n / N) 95% CI (%) 95% CI
Feinstein et al.195914 12 / 116 15 / 113 4.77 0.78 (0.38, 1.59)
Wood et al. 196415 24 / 146 101 / 143 32.00 0.23 (0.16, 0.34)
Feinstein 196516 9 / 136 73 / 101 26.27 0.09 (0.05, 0.17)
Feinstein et al. 196817 33 / 163 124 / 180 36.96 0.29 (0.21, 0.40)
0.1 0.2 0.5 1 2 5 10
Favours intramuscular Favours oral
Fig. 3. Relative risk (95%) of streptococcal throat infection for individuals treated with intramuscular or oral penicillin (CI = confidence interval;
N = total number in group; n = number with outcome).
Review: Penicillin for secondary prevention of rheumatic fever
Comparison: 02 Two-weekly versus 4-weekly penicillin injections
Outcome: 01 Rheumatic fever recurrences
Study 2-weekly injections 4-weekly injections RR (fixed) Weight RR (fixed)
or subcategory (n / N) (n / N) 95% CI (%) 95% CI
Kassem et al.19 24 / 190 41 / 170 100.00 0.52 (0.33, 0.83)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Fig. 4. Relative risk (95% CI) of rheumatic fever recurrence for individuals treated with 2-weekly or 4-weekly penicillin injections (CI =
confidence interval; N = total number in group; n = number with outcome).
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year follow-up data on cardiac sequelae and mortality for the
entire group but the data are not presented separately for each
intervention group. 
Discussion
Main findings
There are two principal findings of this review. First, the
evidence seems to be very strong for intramuscular versus oral
penicillin, with all 4 studies showing an 87 - 96% reduction in
RF recurrence14-17 and a 71 - 91% reduction in streptococcal
throat infection.15-17 Second, the evidence from this review
suggests that more frequent injections are more effective in
preventing RF recurrence than 4-weekly injections.  This
evidence is strong for 2-weekly injections with an almost 50%
reduction in the risk of RF recurrence and a 40% reduction in
streptococcal throat infections compared with 4-weekly
injections.19 The evidence for 3-weekly injections is less strong
and may be even weaker if we take into account the systematic
error introduced by inadequate randomisation and allocation
concealment in the study.18
Quality of included studies
Treatment allocation was not adequately described in 3
studies14,16,17 and was not described at all in 1 study.19 The paper
by Lue et al.18 summarises results of a 12-year prospective
follow-up study which is reported as 3 separate publications.1 8 , 2 0 , 2 1
Allocation to intervention group was initially based on odd or
Review: Penicillin for secondary prevention of rheumatic fever
Comparison: 02 Two-weekly versus 4-weekly penicillin injections
Outcome: 02 Streptococcal throat infections
Study 2-weekly injections 4-weekly injections RR (fixed) Weight RR (fixed)
or subcategory (n / N) (n / N) 95% CI (%) 95% CI
Kassem et al.19 38 / 190 57 / 170 100.00 0.60 (0.42, 0.85)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Fig. 5. Relative risk (95% CI) of streptococcal throat infection for individuals treated with 2-weekly or 4-weekly penicillin injections (CI =
confidence interval; N = total number in group; n = number with outcome).
Review: Penicillin for secondary prevention of rheumatic fever
Comparison: 03 Three-weekly versus 4-weekly intramuscular penicillin
Outcome: 01 Rheumatic fever recurrences
Study 3-weekly injections 4-weekly injections RR (fixed) Weight RR (fixed)
or subcategory (n / N) (n / N) 95% CI (%) 95% CI
Lue et al.18 9 / 124 16 / 125 100.00 0.57 (0.26, 1.23)
0.1 0.2 0.5 1 2 5 10
Favours 3-weekly Favours 4-weekly
Fig. 6. Relative risk (95% CI) of rheumatic fever recurrence for individuals treated with 3-weekly or 4-weekly penicillin injections (CI =
confidence interval; N = total number in group; n = number with outcome).
Review: Penicillin for secondary prevention of rheumatic fever
Comparison: 03 Three-weekly versus 4-weekly intramuscular penicillin
Outcome: 02 Streptococcal throat infections
Study 3-weekly injections 4-weekly injections RR (fixed) Weight RR (fixed)
or subcategory (n / N) (n / N) 95% CI (%) 95% CI
Lue et al.18 39 / 124 59 / 125 100.00 0.67 (0.48, 0.92)
0.1 0.2 0.5 1 2 5 10
Favours 3-weekly Favours 4-weekly
Fig. 7. Relative risk (95% CI) of streptococcal infection for individuals treated with 3-weekly or 4-weekly penicillin injections (CI = confidence
interval; N = total number in group; n = number with outcome).
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even hospital numbers but children recruited between 1985
and 1991 were allocated on the basis of random permutations.
It was not possible to sort out results by method of treatment
allocation. Of the 343 patients in the later study by Feinstein et
al.,17 216 were admitted from the previous trial 16 and  stayed in
the groups to which they had been previously allocated. In the
1965 study by Feinstein ,16 17 patients initially allocated to
intramuscular penicillin were transferred to oral penicillin
because they were not willing to continue receiving injections.
This would have introduced contamination. The outcomes for
these patients were not given separately, so it was not possible
to perform intention-to-treat analysis. Blinding is not possible
when injections are compared with oral tablets and in all
comparisons the authors do not indicate whether outcome
assessment was blind. Follow-up completion was not reported
consistently in the studies. Of the 267 patients initially
randomised in the study by Lue et al.,18 18 were lost to follow-
up and were not accounted for in the final result. 
Therefore, although the evidence is strong, it is based on
studies that were of poor quality. Bias in treatment allocation
would exaggerate the true effect of penicillin injections
compared with tablets and of 2- or 3-weekly injections
compared with 4-weekly injections. When the results are
compared according to methodological quality, there was no
consistent pattern of poor-quality studies showing a greater or
lesser effect size than better-designed studies.
Types of interventions
The oral penicillin doses and schedules differed between the
studies. In 2 studies penicillin tablets were given every day,14,17
and in 1 study tablets were given only during the first 10 days
of every month.16 The earlier studies used potassium penicillin
G.14,16,17 Phenoxymethyl penicillin (penicillin V), the oral
penicillin preparation used today, is more consistently
absorbed and produces high blood levels. There is evidence to
suggest that this form of penicillin results in low frequency of
RF recurrence comparable with benzathine penicillin. 22
Therefore results drawn from this review may not apply to
current oral penicillin preparations. Taking tablets is more
convenient for patients. However, it is easier to ensure
compliance with medication administered by injection. It is
therefore possible that the better results with injections were
simply because this route of penicillin administration ensured
compliance.
Generalisability
Studies included in the review were conducted in Africa,19
Asia,18 and the USA.14-17 However, the baseline risks of RF were
different depending on the geographical area, time period
when studies were conducted and host factors in the
populations studied and the inclusion criteria used in each
study. These factors may limit the applicability of the results in
general. 
Limitations of the review
One limitation of this review is the lack of data on the clinically
relevant outcomes, namely disappearance of heart murmurs,
resolution of valve lesions, mortality due to heart failure and
adverse events. Observational studies suggest that oral
penicillin is safer than parenteral penicillin in terms of allergic
and anaphylactic reactions.23 The International Rheumatic
Fever Study Group, a prospective cohort study from 11
developing countries, showed a 0.2% incidence of anaphylactic
reactions with a fatality rate of 0.05%.24 When viewed in the
light of the evidence in favour of penicillin injections from this
review, these data suggest that the long-term benefits of
prophylactic penicillin injections outweigh the risks.
Implications for practice and research
Intramuscular penicillin seemed to be more effective than oral
penicillin in preventing RF recurrence and streptococcal throat
infections. Two-weekly or 3-weekly injections appeared to be
more effective than 4-weekly injections. Even though trials in
this review were of poor quality, the evidence is  strong and it
is reasonable to promote current guidelines based on this
evidence until further evidence becomes available. There have
been anecdotal reports of sudden deaths following benzathine
penicillin injections given to people with no prior history of
penicillin allergy. In some communities this has led to public
and health care workers preferring oral penicillin. If current
guidelines for RF secondary prevention are to be implemented,
the safety and quality of penicillin injections needs to be
assured. Public health education attempts should focus on
increasing awareness among RF patients with regard to the
need for regular continuous antibiotic prevention and the
options available.
In view of the poor quality of the available evidence, well-
designed randomised controlled trials comparing the
effectiveness of penicillin injections with oral
phenoxymethylpenicillin are required. Such studies should be
of long duration to allow for the measurement of clinically
important outcomes, namely resolution of heart murmurs,
improvement in signs and symptoms of heart failure, reduction
in mortality, and cost-effectiveness of the different treatment
regimens. Pharmacokinetic studies have demonstrated that
penicillin injections given every 2 or 3 weeks ensure penicillin
levels above the minimum inhibitory concentration.25-27 These
findings are in support of the 2-weekly or 3-weekly injections.
There is still a need for well-designed multi-centre randomised
controlled trials to establish whether these surrogate outcomes
translate to clinical benefit. Regarding the safety of
intramuscular penicillin, there is need to set up surveillance
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and adverse drug reaction monitoring systems. Penicillin
injections administered with a local anaesthetic cause less
discomfort and there is a suggestion that they may be
associated with fewer sudden deaths. This question needs to be
addressed in future trials. RF patients and their families should
be involved in discussions to set research priorities that answer
questions relevant to their needs.
Preliminary work on this systematic review was started when
one of the authors (JM) was based in the Department of Medicine,
University of Zimbabwe, with support from AusAid and the
Centre for Clinical Epidemiology and Biostatistics, Newcastle,
Australia. It was subsequently updated and completed in the UK
with methodological and technical support from the Cochrane
Heart Group and a bursary from the Cochrane Health Promotion
and Public Health Field.
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